Abstract:Abstract Purpose Recent findings that human serum contains stably expressed microRNAs (miRNAs) have revealed a great potential of serum miRNA signature as disease fingerprints to predict survival. We used genome-wide serum miRNA expression analysis to investigate the role of serum miRNA in predicting prognosis of NSCLC. Patients and Methods To control disease heterogeneity, we used patients with stage I-IIIa lung adenocarcinoma and squamous cell carcinoma, who were treated with both operation and adjuvant chemotherapies. In the discovery stage, Solexa sequencing followed by individual quantitative RT-PCR (qRT-PCR) assays was used to test the difference in levels of serum miRNAs between 30 longer survival patients (alive and mean survival time: 49.54 months) and 30 shorter survival patients (dead and mean survival time: 9.54 months) matched by age, sex and stage. The detected serum miRNAs were then validated in 243 patients (randomly classified into two subgroups: 120 for the training set and 123 for the testing set). Results Eleven serum miRNAs were found to be altered more than 5-fold by Solexa sequencing between “longer survival” and “shorter survival” groups, and have at least 50 copies in either “longer survival” or “shorter survival” groups. We then performed individual qRT-PCR assay to quantify each of the identified miRNAs and the levels of four miRNAs (miR-486, miR-30d, miR-1 and miR-499) were significantly different between the “longer survival” and “shorter survival” groups (P = 0.0002 for miR-486, 4.30 × 10 −7 for miR-30d, 0.001 for miR-1 and 0.0001 for miR-499). From the training set, high serum expression levels of miR-486 (median: 0.795) and miR-30d (median: 0.680), and low serum expression levels of miR-1 (median: 0.675), miR-499 (median: 0.750) were all individually associated with unfavorable survival. When these threshold values were applied to the testing set, comparable log-rank P values and HRs were also observed, respectively. Results for all the 303 samples including the discovery dataset were also similar to those from the training set. Patients with high serum expression levels of risk miRNAs and low serum expression levels of protective miRNAs had significantly lower MSTs (31.30 months for miR-486, 22.37 months for miR-30d, 22.87 months for miR-1 and 23.73 months for miR-499, all versus not reached). In the combined analysis, we found that patients carrying two or more high-risk miRNAs had significantly increased probability of cancer death in a dose-dependent manner (log rank test: P < 0.0001, HR = 3.14, 95%CI = 1.65-5.97 for 2 high-risk miRNAs carriers, HR = 16.52, 95%CI = 8.62-31.68 for 3 high-risk miRNAs carriers and HR = 34.13, 95%CI = 16.28-71.56 for 4 high-risk miRNAs carriers), compared with those carrying zero or one high-risk miRNA. Conclusion The four-miRNA signature from the serum may serve as a non-invasive predictor for the overall survival of NSCLC. 1 2 Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3002.

A Serum Microrna Signature Predicts Trastuzumab Benefit in HER2-positive Metastatic Breast Cancer Patients

Serum proteomics analysis of candidate predictive biomarker panel for the diagnosis of trastuzumab-based therapy resistant breast cancer.

Original Serum proteomics analysis of candidate predictive biomarker panel for the diagnosis of trastuzumab-based therapy resistant breast cancer

A Mirna-Based Signature Predicts Development of Disease Recurrence in HER2 Positive Early Breast Cancer after Adjuvant Trastuzumab-Based Treatment.

Serum miR-222-3p as a Double-Edged Sword in Predicting Efficacy and Trastuzumab-Induced Cardiotoxicity for HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Target Therapy

Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy

The MiR-200c/FOXP3 Network: A Promising Biomarker for Predicting Trastuzumab Response in HER2-Positive Breast Cancer

Plasma Micrornas Predict Chemoresistance in Patients with Metastatic Breast Cancer.

A 5-Microrna Signature Identified from Serum Microrna Profiling Predicts Survival in Patients with Advanced Stage Non-Small Cell Lung Cancer

Serum Microrna-155 As A Potential Biomarker To Track Disease In Breast Cancer

Serum-Based MicroRNA Signature Predicts Relapse and Therapeutic Outcome of Adjuvant Chemotherapy in Colorectal Cancer Patients

Circulating Micrornas As Specific Biomarkers for Breast Cancer Detection

Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.

Alterations in mRNA profiles of trastuzumab-resistant Her-2-positive breast cancer

Abstract 3002: Serum Mirna Signatures Predict Survival of NSCLC

A 3-Microrna Signature Identified from Serum Predicts Clinical Outcome of the Locally Advanced Gastric Cancer

Plasma miRNA expression could predict clinicopathological characteristics and chemosensitivity in patients with metastatic breast cancer

Circulating MiR-125b As a Marker Predicting Chemoresistance in Breast Cancer

MicroRNA-Based Discovery of Biomarkers, Therapeutic Targets, and Repositioning Drugs for Breast Cancer

A Two-Microrna-based Signature Predicts First-Line Chemotherapy Outcomes in Advanced Colorectal Cancer Patients

Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial